Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gla-300 in insulin-naïve type 2 diabetes patients
NCT04980027Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine U300 in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Treatment Emergent Adverse Events at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
insulin glargine U300
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04980027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980027.